Net sales are distributed geographically between Europe (99.6%) and the United States (0.4); - sales of products (3%). Financial results in 2021: Group net revenues of €484.8 million as compared to €478.1 million in 2020. Galapagos receives transparency notification from FMR LLC Royal Bank of Canada lifted their price objective on [] Investors | Corporate. Galapagos NV (GLPG Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Galapagos announces planned retirement of CEO 首页; 关于; 解决方案; 页宽打印机; HP绘图仪 Ticker: GLPG. Share Price Ticker. Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. +31 6 2909 8028 or Elizabeth Goodwin Director Investor Relations Tel: +31 6 2291 6240 ir@glpg.com << Back. Investors Profil Galapagos. Elizabeth Goodwin-- Vice President, Investor Relations Thank you all for joining us today for the audio webcast of Galapagos' first quarter 2020 results. The stock had previously closed at $49.30. Overeenkomstig de Belgische transparantiewetgeving1 heeft Galapagos op 31 mei 2022 een kennisgeving van belangrijke deelneming ontvangen van FMR LLC, waarin staat dat … Sofie Van Gijsel Senior Director Investor Relations +32 485 19 14 15 ir@glpg.com. Galapagos Thank you, and welcome all to the audio webcast of Galapagos' H1 2021 results. Investors | Corporate. Galapagos Press Releases - galapagoshealth.com